QCBio Research Seminar: Friedrich Simmel, Department of Bioscience, School of Natural Sciences, TU Munich, Germany

Boyer 159 611 Charles E. Young Dr. E., Los Angeles, CA, United States

TITLE: "Electric actuation of DNA-based molecular machines.” ABSTRACT: A wide range of machine-like molecular assemblies have been generated over the past years. Most of them have been driven (or controlled) by DNA hybridization, utilization of buffer changes, or using chemical modifications such as photoswitches. A more recently explored strategy is the use of electrical fields for the manipulation of DNA devices, which enables fast […]

QCBio Webinar: Mapping The Brain With 100 Billion Cells, Is This an Impossible Task?

ZOOM CA, United States

A conversation featuring: Roy Wollman, Ph.D. Professor, UCLA Integrative Biology & Physiology and Chemistry & Biochemistry Jingyi Jessica Li, Ph.D. Professor, UCLA Statistics, Biostatistics, Computational Medicine and Human Genetics Hong-Wei Dong, Ph.D. Professor, UCLA Neurobiology - Director, UCLA Brain Research & Artificial Intelligence Nexus (B.R.A.I.N.) Introduction by: Alexander Hoffmann, Ph.D. Director, Institute for Quantitative & Computational Biosciences - Thomas […]

QCBio/Center for Biological Physics: Gregoire Altan-Bonnet, Principal Investigator – Immunodynamics group Laboratory of Integrative Cancer Immunology NCI, NIH, Bethesda MD

Boyer Hall 130

TITLE: “Stochasticity in cancer immunotherapies: identifying the T cell subset that sparks tumor eradication” ABSTRACT: We use an ex vivo model of tumor eradication to dissect the fundamental variability of clinical outcomes in cancer immunotherapies. We demonstrate that there exists an inherent stochastic variability in immune responses, based on the low abundance of hyper-responsive naïve T cells (so-called […]

QCBio Research Seminar: Gregoire Altan-Bonnet, Principal Investigator – Immunodynamics group Laboratory of Integrative Cancer Immunology NCI, NIH, Bethesda MD

Boyer 159

TITLE: "Stochasticity in cancer immunotherapies: identifying the T cell subset that sparks tumor eradication" ABSTRACT: We use an ex vivo model of tumor eradication to dissect the fundamental variability of clinical outcomes in cancer immunotherapies. We demonstrate that there exists an inherent stochastic variability in immune responses, based on the low abundance of hyper-responsive naïve T cells (so-called Spark T cells) and feedback regulations […]